FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2941009933> ?p ?o ?g. }

• W2941009933 endingPage "644" @default.
• W2941009933 startingPage "638" @default.
• W2941009933 abstract "This study compared the safety and efficacy of prostatic arterial embolization (PAE) with that of trisacryl gelatin microspheres of different sizes for treatment of benign prostatic hyperplasia (BPH).This study consisted of a single-center, randomized controlled clinical trial in 138 patients who underwent PAE for BPH between July 2015 and December 2016. Patients were randomized to PAE using microspheres of different sizes: group A patients were treated with microspheres 100-300 μm, group B with 300-500 μm, and group C with 100-300 μm followed by 300-500 μm. All patients were evaluated before and at 1, 3, 6, 12, and 18 months after PAE. Baseline data were comparable across the 3 groups, using the following mean International Prostate Symptom Score/quality of life (IPSS/QoL); prostate volume (PV) scores, respectively: 23.0/4.14; 87.9 cm3 (group A); 23.0/4.09; 89.0 cm3 (group B); and 24.2/4.29; 81.0 cm3 (group C) (P > 0.05).Mean IPSS/QoL scores; PV after PAE were: 9.98/2.49; 65.1 cm3 (group A); 8.24/2.26; 63.1 cm3 (group B); and 10.1/2.69; 53.1 cm3 (group C) (P = 0.23; P = 0.39; P = 0.24). There were 26 clinical failures. The cumulative probabilities of clinical success at 18 months were 76.7% in group A, 82.6% in group B, and 83.3% in group C (P = 0.68). Nontarget embolization was prevented in 6 patients by coil embolization. All adverse events were mild and self-limited with rates of 86.0% in group A (37 of 43); 41.3% in group B (19 of 46); and 58.3% in group C (28 of 48) (P < 0.001). Dysuria was the most frequent adverse event (28 of 137 [20.4%]).PAE outcomes were not significantly different among microspheres of different sizes. The use of 100- to 300-μm microspheres was associated with an increased risk of minor adverse events." @default.
• W2941009933 created "2019-05-03" @default.
• W2941009933 creator A5000713315 @default.
• W2941009933 creator A5021770094 @default.
• W2941009933 creator A5030298879 @default.
• W2941009933 creator A5048981429 @default.
• W2941009933 creator A5068261282 @default.
• W2941009933 creator A5090041666 @default.
• W2941009933 date "2019-05-01" @default.
• W2941009933 modified "2023-10-18" @default.
• W2941009933 title "Prostatic Artery Embolization for Benign Prostatic Hyperplasia: Prospective Randomized Trial of 100–300 μm versus 300–500 μm versus 100- to 300-μm + 300- to 500-μm Embospheres" @default.
• W2941009933 cites W1616423488 @default.
• W2941009933 cites W1964268361 @default.
• W2941009933 cites W1966080013 @default.
• W2941009933 cites W2013816708 @default.
• W2941009933 cites W2014608302 @default.
• W2941009933 cites W2050026651 @default.
• W2941009933 cites W2061237506 @default.
• W2941009933 cites W2062514036 @default.
• W2941009933 cites W2065561000 @default.
• W2941009933 cites W2099357343 @default.
• W2941009933 cites W2104882900 @default.
• W2941009933 cites W2109819743 @default.
• W2941009933 cites W2127096827 @default.
• W2941009933 cites W2136497502 @default.
• W2941009933 cites W2144563350 @default.
• W2941009933 cites W2156170091 @default.
• W2941009933 cites W2168721648 @default.
• W2941009933 cites W2330293894 @default.
• W2941009933 cites W2403351495 @default.
• W2941009933 cites W2504455853 @default.
• W2941009933 cites W2895631443 @default.
• W2941009933 cites W2907530813 @default.
• W2941009933 cites W2913728295 @default.
• W2941009933 doi "https://doi.org/10.1016/j.jvir.2019.02.014" @default.
• W2941009933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31029381" @default.
• W2941009933 hasPublicationYear "2019" @default.
• W2941009933 type Work @default.
• W2941009933 sameAs 2941009933 @default.
• W2941009933 citedByCount "41" @default.
• W2941009933 countsByYear W29410099332020 @default.
• W2941009933 countsByYear W29410099332021 @default.
• W2941009933 countsByYear W29410099332022 @default.
• W2941009933 countsByYear W29410099332023 @default.
• W2941009933 crossrefType "journal-article" @default.
• W2941009933 hasAuthorship W2941009933A5000713315 @default.
• W2941009933 hasAuthorship W2941009933A5021770094 @default.
• W2941009933 hasAuthorship W2941009933A5030298879 @default.
• W2941009933 hasAuthorship W2941009933A5048981429 @default.
• W2941009933 hasAuthorship W2941009933A5068261282 @default.
• W2941009933 hasAuthorship W2941009933A5090041666 @default.
• W2941009933 hasConcept C121608353 @default.
• W2941009933 hasConcept C126322002 @default.
• W2941009933 hasConcept C126894567 @default.
• W2941009933 hasConcept C141071460 @default.
• W2941009933 hasConcept C159110408 @default.
• W2941009933 hasConcept C168563851 @default.
• W2941009933 hasConcept C197934379 @default.
• W2941009933 hasConcept C2776035437 @default.
• W2941009933 hasConcept C2776235491 @default.
• W2941009933 hasConcept C2776547966 @default.
• W2941009933 hasConcept C2777562237 @default.
• W2941009933 hasConcept C2777785397 @default.
• W2941009933 hasConcept C2779478474 @default.
• W2941009933 hasConcept C2779951463 @default.
• W2941009933 hasConcept C535046627 @default.
• W2941009933 hasConcept C71924100 @default.
• W2941009933 hasConceptScore W2941009933C121608353 @default.
• W2941009933 hasConceptScore W2941009933C126322002 @default.
• W2941009933 hasConceptScore W2941009933C126894567 @default.
• W2941009933 hasConceptScore W2941009933C141071460 @default.
• W2941009933 hasConceptScore W2941009933C159110408 @default.
• W2941009933 hasConceptScore W2941009933C168563851 @default.
• W2941009933 hasConceptScore W2941009933C197934379 @default.
• W2941009933 hasConceptScore W2941009933C2776035437 @default.
• W2941009933 hasConceptScore W2941009933C2776235491 @default.
• W2941009933 hasConceptScore W2941009933C2776547966 @default.
• W2941009933 hasConceptScore W2941009933C2777562237 @default.
• W2941009933 hasConceptScore W2941009933C2777785397 @default.
• W2941009933 hasConceptScore W2941009933C2779478474 @default.
• W2941009933 hasConceptScore W2941009933C2779951463 @default.
• W2941009933 hasConceptScore W2941009933C535046627 @default.
• W2941009933 hasConceptScore W2941009933C71924100 @default.
• W2941009933 hasIssue "5" @default.
• W2941009933 hasLocation W29410099331 @default.
• W2941009933 hasLocation W29410099332 @default.
• W2941009933 hasOpenAccess W2941009933 @default.
• W2941009933 hasPrimaryLocation W29410099331 @default.
• W2941009933 hasRelatedWork W1978630268 @default.
• W2941009933 hasRelatedWork W1987948455 @default.
• W2941009933 hasRelatedWork W1998870364 @default.
• W2941009933 hasRelatedWork W2116616598 @default.
• W2941009933 hasRelatedWork W2330542927 @default.
• W2941009933 hasRelatedWork W2361181619 @default.
• W2941009933 hasRelatedWork W2362715014 @default.
• W2941009933 hasRelatedWork W2368894981 @default.
• W2941009933 hasRelatedWork W2386487224 @default.
• W2941009933 hasRelatedWork W2984530377 @default.

• next